Multidrug-resistant tuberculosis (MDR-TB) treatment data for the 43 cases diagnosed and treated in Finland, 2007–2016#
| Cases, n (%) | Duration, median (IQR) | Adverse events, n (%) | Drugs, median (IQR) | |
| Injectable drug¶ | 39 (90.7) | 6.2 (5.2–7.4) months | 22 (56.4) | |
| Linezolid | 38 (88.4) | 9.6 (5.6–14.8) months | 26 (68.4) | |
| Fluoroquinolone+ | 40 (93.0) | 23.3 (15.8–24.8) months | 10 (25.0) | |
| Clofazimine | 23 (53.5) | 12.3 (5.6–21.1) months | 2 (8.7) | |
| Bedaquiline§ | 5 (11.6) | 5.9 (4.5–15.6) months | 0 (0) | |
| Duration of effective MDR-TB treatment | 23.8 (17.8–25.8) months | |||
| Adverse event for any drug | 38 (88.4) | |||
| Number of drugs in intensive phase | 6 (5–6) | |||
| Number of drugs in continuation phase | 4 (4–5) | |||
| Duration of hospitalisation | 50 (38–108) days | |||
| Cases with all MDR-TB medicines paused | 14 (32.6) | |||
| Duration of pauses for cases with pauses in medication | 9.0 (5.5–14.0) days | |||
| DOT used | 42 (97.7) |
IQR: interquartile range; DOT: directly observed treatment. #: cases that received only standard tuberculosis treatment with first-line drugs (n=1) or left Finland during MDR-TB treatment (n=3) were excluded; ¶: amikacin (n=37), streptomycin (n=2), non-recipient of an injectable drug due to drug resistance (n=3) and due to young age (n=1); +: non-recipient of fluoroquinolone due to drug resistance (n=3); §: extensively drug-resistant (n=3), pre-extensively drug-resistant (n=1), MDR (n=1).